Comparative Pharmacology
Head-to-head clinical analysis: MACUGEN versus MVASI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACUGEN versus MVASI.
MACUGEN vs MVASI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pegaptanib is a pegylated modified oligonucleotide that binds to and inhibits vascular endothelial growth factor (VEGF-165), reducing angiogenesis and vascular permeability.
Monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing binding to VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and tumor growth.
Intravitreal injection of 0.3 mg (0.09 mL) once every 6 weeks.
5 mg/kg intravenously every 2 weeks for metastatic colorectal cancer; 15 mg/kg intravenously every 3 weeks for non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer.
None Documented
None Documented
The terminal elimination half-life in plasma is approximately 10 days following intravitreal administration, consistent with slow clearance from the vitreous cavity and systemic absorption.
Approximately 20 days (range 11–50 days); typical dosing interval every 2–3 weeks.
Pegaptanib is eliminated primarily via renal excretion, with the parent compound and metabolites excreted in urine accounting for >90% of the administered dose. Biliary/fecal elimination is negligible (<5%).
Primarily metabolized via reticuloendothelial system; no significant renal or biliary excretion of intact drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor